Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146631 | 1.00 | LMNA (0.46) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL3156406 | 0.86 | IDO1 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL281883 | 0.86 | IDO1 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL282798 | 0.86 | IDO1 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL18548557 | 0.85 | ADRB3 (0.46) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL29493206 | 0.85 | ADRB3 (0.46) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL98267 | 0.84 | ADRB3 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL1560927 | 0.84 | ADRB3 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL3917396 | 0.84 | ADRB3 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL13849930 | 0.83 | ADRB1 (0.48) | LMNAADRB3ADRB1ADRB2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070087-B1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3070087-A1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2739625-B1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9108981-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-26 | — | — | US | disclosed |
| US-8901115-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| CN-101277933-A | Substituted propylamine derivatives and methods of their use | WYETH CORP (US) | 2008-10-01 | — | — | CN | disclosed |
| EP-1934178-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007041257-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| CN-1267560-C | Process for preparing stereoisomer carboxylate | BASF AG (DE) | 2006-08-02 | — | — | CN | disclosed |
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| CN-1266904-A | Process for preparing stereoisomer carboxylate | BASF AG (DE) | 2000-09-20 | — | — | CN | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | LMNA 3099/4885ADRB3 140/4885ADRB1 184/4885 |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | LMNA 493/4885ADRB3 4773/4885ADRB1 4085/4885 |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | LMNA 449/4885ADRB3 1241/4885ADRB1 1302/4885 |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | LMNA 493/4885ADRB3 4773/4885ADRB1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.